Man Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Man Group’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-337,271	Closed	-$13.8M	–	2281
2024 Q2	$13.8M	Sell	337,271 -640,275	-65%	-$26.7M	0.03%	566
2024 Q1	$41.3M	Buy	977,546 +885,686	+964%	+$37.2M	0.1%	217
2023 Q4	$3.89M	Buy	+91,860	New	+$2.64M	0.01%	1058
2023 Q3	–	Sell	-152,117	Closed	-$4.84M	–	2221
2023 Q2	$4.84M	Buy	+152,117	New	+$4.67M	0.01%	884
2022 Q2	–	Hold	0	–	–	–	1703
2021 Q2	–	Sell	-13,468	Closed	-$185K	–	2125
2021 Q1	$185K	Buy	+13,468	New	+$197K	﹤0.01%	1755

Other funds holding CERE

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Man Group's CERE Position: Q3 2024 in Review

Man Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 337,271 shares — an estimated $13.8M sold.

Man Group first reported a position in CERE in Q1 2021 and held it in 5 quarters. The position peaked at $41.3M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Man Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Man Group sold 337,271 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $13.8M.
Man Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Man Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $41.3M in Q1 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Man Group's 13F filing for Q3 2024, filed 14 Nov 2024.